Author: Huijie Bian; Zhao-Hui Zheng; Ding Wei; Zheng Zhang; Wen-Zhen Kang; Chun-Qiu Hao; Ke Dong; Wen Kang; Jie-Lai Xia; Jin-Lin Miao; Rong-Hua Xie; Bin Wang; Xiu-Xuan Sun; Xiang-Min Yang; Peng Lin; Jie-Jie Geng; Ke Wang; Hong-Yong Cui; Kui Zhang; Xiao-Chun Chen; Hao Tang; Hong Du; Na Yao; Shuang-Shuang Liu; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Gang Nan; Qing-Yi Wang; Jian-Qi Lian; Zhi-Nan Chen; Ping Zhu
Title: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial Document date: 2020_3_24
ID: 6g34qwer_31
Snippet: It was reported that lymphocytopenia is a typical characteristics and correlated with the prognosis of COVID-19 pneumonia. In our study, we compared the lymphocyte count between baseline and post-treatment in both groups. As shown in figure 6A , in observation period (day 7 to 28), the percentages of patients with a normal lymphocyte count (>0.8×10 9 /L) were increased in both groups, while the improvement in meplazumab group was more notable. C.....
Document: It was reported that lymphocytopenia is a typical characteristics and correlated with the prognosis of COVID-19 pneumonia. In our study, we compared the lymphocyte count between baseline and post-treatment in both groups. As shown in figure 6A , in observation period (day 7 to 28), the percentages of patients with a normal lymphocyte count (>0.8×10 9 /L) were increased in both groups, while the improvement in meplazumab group was more notable. Compared to baseline, the percentage in meplazumab group was improved significantly as early as day 7 (p=0.031), but no significance difference was detected in control group over the follow-up period.
Search related documents:
Co phrase search for related documents- baseline compare and follow period: 1, 2
- baseline compare and post treatment: 1, 2
- baseline compare and post treatment baseline: 1
- baseline compare and significance difference: 1
- control group and follow period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control group and group increase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control group and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control group and meplazumab group: 1, 2, 3, 4, 5, 6, 7, 8, 9
- control group and observation period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- control group and pneumonia prognosis: 1, 2, 3, 4, 5, 6
- control group and post treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control group and post treatment baseline: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- control group and significance difference: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- control group and significantly improve: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- follow period and pneumonia prognosis: 1, 2
- follow period and post treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- follow period and post treatment baseline: 1, 2, 3
- follow period and significance difference: 1, 2
- follow period and significantly improve: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date